HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Myers, T. J. Articles by Frazier, O. H. Search for Related Content PubMed PubMed Citation Articles by Myers, T. J. Articles by Frazier, O. H. Related Collections Mechanical Circulatory Assistance

Ann Thorac Surg 2003;75:S79-S85
© 2003 The Society of Thoracic Surgeons

---

Supplement

Continuous flow pumps and total artificial hearts: management issues

^a Cardiovascular Surgical Research Laboratories, Texas Heart Institute at St. Luke’s Episcopal Hospital, Houston, Texas, USA

^* Address reprint requests to Mr Myers, Texas Heart Institute, 6770 Bertner Ave, MC 1-268, Houston, TX 77030, USA
e-mail: tmyers{at}heart.thi.tmc.edu

Presented at the Heart Failure & Circulatory Support Summit, Cleveland, OH, Aug 22–25, 2002.

Abstract

Feasibility studies are underway for new axial flow ventricular assist systems and with a total artificial heart (TAH). The axial flow pumps provide continuous flow from the left ventricle (LV) to the aorta; the TAH provides pulsatile flow to the pulmonary and systemic circulation. Understanding the differences between these systems is necessary for appropriate patient selection and management. We compared the Jarvik 2000 axial-flow pump and the AbioCor TAH. The Jarvik 2000 pump is placed in the LV with its outflow graft anastomosed to the aorta. This system is used for bridge-to-transplantation and destination therapy. The AbioCor TAH provides complete circulatory support. The AbioCor is used for destination therapy in patients expected to die in less than 30 days. Worldwide, 45 patients have received the Jarvik 2000 as a bridge to transplantation (n = 34) or destination therapy (n = 11) for an average duration of support of 132.8 days (5 to 853 days). In 30 bridge-to-transplantation cases, 14 patients (47%) have undergone heart transplantation, 5 (17%) continue to be supported with the Jarvik 2000 device, and 11 (37%) have died. Five of 7 patients supported by the AbioCor TAH survived beyond the perioperative period; 4 were ambulatory, 2 were discharged from the hospital, and 1 is at home 13 months after implantation. Anticoagulation therapy and infection management are necessary for both systems. Therapy with inotropic agents, vasoactive drugs, a pacemaker, and electrolyte normalization is necessary for Jarvik patients. AbioCor-supported patients do not require medications to support heart function. Vasoactive agents may be useful for controlling blood pressure.

This article has been cited by other articles:

				E. D. Feller, E. N. Sorensen, M. Haddad, R. N. Pierson, F. L. Johnson, J. M. Brown, and B. P. Griffith Clinical Outcomes Are Similar in Pulsatile and Nonpulsatile Left Ventricular Assist Device Recipients Ann. Thorac. Surg., March 1, 2007; 83(3): 1082 - 1088. [Abstract] [Full Text] [PDF]

				S. Scolletta, I. D Gregoric, L. Muzzi, B. Radovancevic, and O H. Frazier Pulse wave analysis to assess systemic blood flow during mechanical biventricular support. Perfusion, January 1, 2007; 22(1): 63 - 66. [Abstract] [PDF]